Terms: = Liver cancer AND PR, PGR, progesterone receptor AND Treatment
1160 results:
1. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.
Zhang X; Zhu X; Zhong J; Zhao Y; Zhang X; Zhang W; Ye F; Yang C; Xue J; Xiong R; Wang J; Shen S; Pan Y; Li D; Song T; Bi X; Sun H; Xiang B; Gu S; Wen T; Lu S; Chen Y; Yin T; Liu L; Kuang M; Xu L; Li D; Cai J
Sci Rep; 2024 Apr; 14(1):9745. PubMed ID: 38679630
[TBL] [Abstract] [Full Text] [Related]
2. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract] [Full Text] [Related]
3. Investigation of deep learning model for predicting immune checkpoint inhibitor treatment efficacy on contrast-enhanced computed tomography images of hepatocellular carcinoma.
Nakao Y; Nishihara T; Sasaki R; Fukushima M; Miuma S; Miyaaki H; Akazawa Y; Nakao K
Sci Rep; 2024 Mar; 14(1):6576. PubMed ID: 38503827
[TBL] [Abstract] [Full Text] [Related]
4. Activity of Tepotinib in Hepatocellular Carcinoma With High-Level
Qin S; Pan H; Blanc JF; Grando V; Lim HY; Chang XY; O'Brate A; Stroh C; Friese-Hamim M; Albers J; Johne A; Faivre S
JCO Precis Oncol; 2024 Feb; 8():e2300328. PubMed ID: 38354329
[TBL] [Abstract] [Full Text] [Related]
5. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study.
Yi L; Ning Z; Xu L; Shen Y; Zhu X; Yu W; Xie J; Meng Z
ESMO Open; 2024 Feb; 9(2):102239. PubMed ID: 38325225
[TBL] [Abstract] [Full Text] [Related]
6. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
Kikuchi K; Ogawa M; Sasaki A
J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
[TBL] [Abstract] [Full Text] [Related]
7. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract] [Full Text] [Related]
8. [Our Experience with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma].
Shimizu J; Yamashita M; Odagiri K; Takeyama H; Yanagimoto Y; Suzuki Y; Ikenaga M; Kawase T; Imamura H; Dono K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1513-1515. PubMed ID: 38303325
[TBL] [Abstract] [Full Text] [Related]
9. [A Case of Triple Negative Breast cancer with Successful Control of Recurrent Disease Activity for More than Ten Years].
Yabe N; Watanuki R; Harada Y; Kondo A; Yanagisawa T; Maeda H; Kishi M; Yoshikawa T; Osumi K; Kamiya N; Sotome K; Ishii Y; Jinno H; Ikeda T; Watanabe M
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1759-1761. PubMed ID: 38303198
[TBL] [Abstract] [Full Text] [Related]
10. [A Case of HER2-Positive Advanced Breast cancer Who Was Able to Start and Continue Chemotherapy Despite liver Damage Due to Diffuse liver Metastasis].
Fujimoto T; Maeda N; Ioka T; Nagano H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1739-1741. PubMed ID: 38303191
[TBL] [Abstract] [Full Text] [Related]
11. [A Case of Recurrent Gastric cancer with Long-Term Control via Two Resections and Multidisciplinary treatment Including Nivolumab].
Bungo M; Takeno A; Hirao M; Hamakawa T; Yamamoto M; Matsui Y; Tokuyama S; Toshiyama R; Kawai K; Takahashi Y; Sakai K; Doi T; Goto K; Kato T; Takami K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1715-1717. PubMed ID: 38303183
[TBL] [Abstract] [Full Text] [Related]
12. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.
Liu D; Mu H; Liu C; Zhang W; Cui Y; Wu Q; Zhu X; Fang F; Zhang W; Xing W; Li Q; Song T; Lu W; Li H
Neoplasma; 2023 Dec; 70(6):811-818. PubMed ID: 38247334
[TBL] [Abstract] [Full Text] [Related]
13. [Efficacy analysis of hepatic arterial infusion chemotherapy combined with targeted and immune therapy followed by
Wang M; Zhou ZG; Lu TY; Du KP; Li S; Gao F; Li YD; Gao MY
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):290-296. PubMed ID: 38246774
[No Abstract] [Full Text] [Related]
14. Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.
Peng K; Li Y; Su H; Lan C; Huang Z; Wei Y; Liao X; Peng M; Peng T; Zhu G
Front Immunol; 2023; 14():1325445. PubMed ID: 38173715
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.
Wang W; Lei W; Fang Z; Jiang R; Wang X
BMC Cancer; 2024 Jan; 24(1):1. PubMed ID: 38166784
[TBL] [Abstract] [Full Text] [Related]
16. Prediction of SBRT response in liver cancer by combining original and delta cone-beam CT radiomics: a pilot study.
Yang P; Shan J; Ge X; Zhou Q; Ding M; Niu T; Du J
Phys Eng Sci Med; 2024 Mar; 47(1):295-307. PubMed ID: 38165634
[TBL] [Abstract] [Full Text] [Related]
17. Associations of circulating immunomarkers with the efficacy of immunotherapy for primary hepatic carcinoma.
Liu S; Xu W; Shu H; Dai Y; Du Y; Liu Y; Huang L; Sun G
Cancer Med; 2023 Dec; 12(24):21830-21848. PubMed ID: 38054365
[TBL] [Abstract] [Full Text] [Related]
18. A Case Report of a Rare ER+, PR- Pure Metaplastic Breast Squamous Cell Carcinoma with HER2 Overexpression.
Adam SA; Kamaruddin KN; Abd Shukor N; Abdullah Suhaimi SN; Ismail F; Md Yasin M
Am J Case Rep; 2023 Dec; 24():e941448. PubMed ID: 38048289
[TBL] [Abstract] [Full Text] [Related]
19. [A Case of Long-Term Survival without Recurrence after Completion of Immunotherapy Due to Response of Third- Line Nivolumab for liver Metastasis Recurrence of Esophagogastric Junction cancer].
Ryuzaki T; Sentsui T; Amagai H; Sasagawa S; Kobayashi S; Tsukamoto S; Koide Y; Matsubara H
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1126-1129. PubMed ID: 38035852
[TBL] [Abstract] [Full Text] [Related]
20. Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
Furubayashi N; Minato A; Tomoda T; Hori Y; Kiyoshima K; Negishi T; Haraguchi Y; Koga T; Kuroiwa K; Fujimoto N; Nakamura M
Anticancer Res; 2023 Dec; 43(12):5689-5698. PubMed ID: 38030199
[TBL] [Abstract] [Full Text] [Related]
[Next]
